Almac Group boosts U.S. footprint with new jobs, investment

Ireland and U.S.-based CDMO Almac will inject $5.2 million into its U.S. ops and created around 80 new jobs in research heartland North Carolina as part of its “celebration” of its 20 years in North America.

“This latest investment and increase in capacity at our Durham facility is a sign of our continuing commitment to offer market driven solutions to our client base,” says Donna Christopher, global VP of operations at Almac Clinical Services, in a statement.

“We are delighted to mark our 20th year in the US with such a significant announcement--once again reinforcing our dedication to global expansion.”

Whitepaper Download

Reducing the Complexity and Costs of Channel Planning and Logistics

How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business.

The money will go toward the boosting its Clinical Services facility, as well as its Diagnostics and Clinical Technologies operations in the CRO-laden state.

Robert Dunlop, president and MD at Almac Clinical Services, added: “We are delighted to announce further investment in our Durham facilities enabling us to continue to support our clients’ needs and meet the increased demands for our integrated services and I look forward to our continuing success over the next twenty years and beyond.”

Read more on

Suggested Articles

Viva Biotech is putting down $80 million to buy preclinical contract research organization SYNthesis and boost its outsourcing business.

Popular research network provider TriNetX has seen major interest from The Carlyle Group as it buys up a majority stake in the company.

Clinical trial firm Phesi’s new report is some grim reading for the life science industry: Studies for new drugs are still suffering.